When Will Retatrutide Be Available? FDA Status & Timeline

Last updated: March 2026

Retatrutide just proved it can strip nearly 29% of body weight in clinical trials — and you still can't get it. Here's exactly where it stands, when that changes, and what you can do right now while waiting.

Key Takeaways

• Retatrutide is not FDA approved. As of March 2026, it remains an investigational drug. No pharmacy — compounding or retail — can legally dispense it under a standard prescription.
• The most likely approval window is late 2027 to early 2028. Not 2026. Not six months from now. Lilly's NDA hasn't even been filed yet.
• The "discontinuation" rumors are false. Retatrutide was never discontinued. That confusion comes from a Phase 2 trial that simply ended (as trials do). The drug is very much alive.
• You can access compounded retatrutide right now through certain peptide suppliers — legally gray in the US, but real and widely used.
• TRIUMPH-4 delivered the biggest Phase 3 weight-loss result in pharmaceutical history — 28.7% mean body weight reduction at 68 weeks. That's not a typo.
• The FDA timeline depends heavily on how many more TRIUMPH readouts they need before accepting the NDA.

The question everyone's asking is simple: when can I actually get this? Honestly, the answer is still frustrating. But it's clearer than it was six months ago. The Phase 3 data is rolling in, Eli Lilly has given public timeline guidance, and the regulatory path is mapped — even if it's slower than any of us want.

Let's break down exactly where retatrutide stands, when things are actually going to move, and what your options are while the FDA clock ticks.

What Retatrutide Is (Quick Primer)

Retatrutide (code name LY3437943) is a triple agonist — meaning it activates three hormone receptors simultaneously: GLP-1, GIP, and glucagon. Every other approved weight-loss drug on the market hits one or two of those targets. Retatrutide hits all three.

That third target — glucagon — is the key difference. It signals the liver to burn more fat and ramps up energy expenditure in ways that semaglutide and tirzepatide simply don't. The result? Weight loss numbers that genuinely broke records in clinical testing.

For a deeper look at the mechanism, check out our what is retatrutide.

Current FDA Status: Where Things Stand in March 2026

Retatrutide is in Phase 3 clinical trials under Eli Lilly's TRIUMPH program. No New Drug Application (NDA) has been submitted to the FDA yet — Lilly needs to finish collecting Phase 3 data first.

Here's what's happened:

• December 2025: TRIUMPH-4 (obesity + knee osteoarthritis) announced results — 28.7% mean weight loss at the 12 mg dose. Historic.
• March 2026: First Phase 3 data from TRANSCEND-T2D-1 (Type 2 Diabetes) released, showing significant A1C and weight reductions.
• Still pending: TRIUMPH-1 (the main obesity pivotal trial), TRIUMPH-2, TRIUMPH-3, TRIUMPH-8, and the SYNERGY MASH trial.

Eli Lilly's own public guidance from the Q4 2025 earnings call: NDA filing expected in late 2026. That puts FDA review — under even a Priority Review designation — completing no earlier than mid-2027.

The TRIUMPH Phase 3 Program: What's Still In Progress

The TRIUMPH program is enormous. It's not one trial — it's a constellation of them covering different patient populations. Before Lilly files the NDA, they need pivotal data from multiple arms.

TRIUMPH-1 is the big one. That's the broad obesity pivotal trial — the data the FDA will primarily use to evaluate the NDA for an obesity indication. Until TRIUMPH-1 reads out, the NDA clock doesn't really start.

Retatrutide FDA Approval Timeline: The Realistic Roadmap

Here's how the regulatory pathway looks from today:

Late 2026 — NDA Filing After TRIUMPH-1 and other core trials report, Eli Lilly compiles the full data package and submits. This takes 6–12 months of preparation after data collection closes — and Lilly will likely be doing rolling prep in parallel.

Early 2027 — FDA Filing Review The FDA gets 60 days to accept or reject the application. Assuming acceptance, the clock starts for full review.

Early–Mid 2027 — Priority Review Decision If the FDA grants Priority Review (6–8 months instead of the standard 10–12), approval could land as early as mid-2027. Given the magnitude of TRIUMPH-4's results, Priority Review is plausible — but not guaranteed. The dysesthesia side effect (abnormal sensory sensations in ~21% of patients at 12 mg) will likely trigger scrutiny.

Mid-2027 (Optimistic) to Early 2028 (Base Case) Most analysts and medical commentators peg the realistic approval window at late 2027 to early 2028. That's the scenario where everything goes relatively smoothly.

2028+ (Delayed Scenario) If the FDA wants additional cardiovascular outcomes data, or if the dysesthesia signal requires extra safety studies, approval could slip to 2028 or beyond.

Comparing Retatrutide to Current Options

The gap between retatrutide and everything currently available isn't marginal — it's massive. That's why patience is actually worth it here.

Let's Address the "Retatrutide Discontinuation" Confusion Directly

You've probably seen headlines or forum posts claiming retatrutide was "discontinued" or "cancelled." This is completely wrong, and here's where it came from.

Back when Phase 2 trials wrapped up, several clinical trial listings moved to "completed" status. Non-experts (and bad journalists) misread this as the program being killed. It wasn't. Phase 2 ending is a normal milestone — it's literally what's supposed to happen before Phase 3 starts.

Retatrutide has not been discontinued. Eli Lilly has continued investing billions into the TRIUMPH Phase 3 program. New Phase 3 data is actively releasing in 2026. The company publicly reaffirmed their NDA timeline on their Q4 2025 earnings call.

If you're seeing "discontinued" anywhere — ignore it.

Is Retatrutide Available in the USA Right Now?

Officially? No. Practically? Sort of — depending on how you define "available."

Through standard medical channels — your doctor writing a prescription, a pharmacy filling it — retatrutide is not available anywhere in the United States. This is unambiguous.

What does exist:

1. Clinical Trials If you qualify (BMI ≥30, or ≥27 with a weight-related condition, age 18+, no recent use of other weight loss meds), you can enroll. You'd get pharmaceutical-grade retatrutide at no cost, with full medical supervision. The catch: you might receive placebo, and sites are increasingly filled as enrollment closes.

Check ClinicalTrials.gov for currently enrolling sites near you.

2. Compounded Retatrutide via Peptide Suppliers This is where it gets real. A segment of the peptide market sells retatrutide — sometimes labeled as "R-30" or similar — for self-administration. Quality varies enormously between suppliers. This is not the same as FDA-approved pharmaceutical-grade product.

3. Offshore or Gray Market Some international suppliers ship to the US. Customs enforcement varies. Risk is substantially higher.

The most reliable source we've found for third-party tested compounded retatrutide is Ascension Peptides — they offer certificates of analysis, competitive pricing, and fast US shipping.

For a full breakdown of sourcing options, read our where to buy retatrutide.

How Retatrutide Compares to Semaglutide: Worth the Wait?

If you're currently on Wegovy (semaglutide) or considering it, you're probably wondering whether to hold out for retatrutide instead.

Blunt take: for most people, starting something now makes more sense than waiting 18+ months. Semaglutide and tirzepatide are genuinely effective. You can lose significant weight while the FDA finishes its review.

That said — if you're already at your goal or close, or if GLP-1 monotherapy hasn't delivered the results you wanted, retatrutide may be worth the patience.

Read our full retatrutide vs semaglutide comparison for a detailed breakdown of efficacy, side effects, and who each drug is best for.

What Happens After FDA Approval

Even after approval, retatrutide won't appear on pharmacy shelves overnight.

Manufacturing ramp-up: Lilly will need months to produce commercial-scale supply. Ozempic and Wegovy faced years of shortages after approval. Retatrutide demand will be enormous.

Insurance coverage: If approved for obesity only, expect inconsistent coverage. Many plans still exclude weight management drugs. If it gets a diabetes indication too (TRANSCEND data permitting), coverage will be much broader.

Price: Expect pricing in the $1,000–$1,400/month range without insurance, similar to Zepbound and Wegovy. Lilly's pricing strategy will significantly affect accessibility.

Compounding status: Once retatrutide is FDA-approved and commercially available, it will likely be removed from compounding pharmacy access (the same thing happened with semaglutide when shortages ended). The peptide market will shrink dramatically.

If you want access to retatrutide now — before approval, before the rules change — Ascension Peptides is your best current option.

Global Availability: When Will Other Countries Get It?

The FDA moves first. Then everyone else follows:

UK residents get a bit of a shortcut through MHRA's parallel review process. EU and Australia will likely wait a bit longer. In all cases, reimbursement/coverage approvals add additional months to practical access.

FAQs: Retatrutide Availability

Is retatrutide FDA approved? No. As of March 2026, retatrutide (LY3437943) has not received FDA approval for any indication. Eli Lilly has not yet submitted an NDA. The drug is in Phase 3 clinical trials under the TRIUMPH program.

When will retatrutide be available? The most realistic timeline is late 2027 to early 2028 for FDA approval, assuming the NDA is filed in late 2026 and receives Priority Review. A full commercial launch with widespread pharmacy availability would follow 3–6 months after approval.

Was retatrutide discontinued? No. This is a persistent myth. Phase 2 trials completed — which is normal — and some trial registrations show "completed" status. Eli Lilly never cancelled the retatrutide program. Phase 3 TRIUMPH trials are actively running and reporting results.

Can I get retatrutide now? You can access it through clinical trial enrollment (if you qualify), or through the peptide/compounding market from suppliers like Ascension Peptides. For a full breakdown of how to get retatrutide through current available channels, that guide covers the options in detail. Neither is the same as an FDA-approved prescription.

How much will retatrutide cost? Pricing hasn't been announced. Based on comparable GLP-1 drugs at launch, expect $1,000–$1,400/month without insurance. With a diabetes indication, insurance coverage may be more consistent than for obesity-only approval.

What dose will be available? TRIUMPH trials tested 4 mg, 8 mg, and 12 mg weekly doses. TRIUMPH-4 showed 28.7% weight loss at 12 mg. The commercial formulation will likely include multiple titration doses, similar to Zepbound's dosing ladder.

Will retatrutide replace tirzepatide? Probably not immediately. Tirzepatide (Zepbound/Mounjaro) will remain the standard of care until retatrutide reaches wide availability. Plenty of people will achieve their goals with tirzepatide before retatrutide ever hits pharmacy shelves.

Is retatrutide available in Canada or the UK? No — not through standard medical channels. Both countries are awaiting FDA approval, after which Health Canada and MHRA would conduct their own reviews. Clinical trial sites exist in both countries.

The Bottom Line

Retatrutide is coming. The data is extraordinary. The timeline is painful but now fairly clear: NDA in late 2026, FDA decision in 2027–2028. Early 2028 for actual pharmacy availability is the most honest estimate.

Between now and then, your options are clinical trial enrollment or peptide suppliers. If you're serious about accessing retatrutide before approval, Ascension Peptides is the vendor we'd point you toward — third-party tested, US-based, and with a track record in the GLP-1 peptide space.

Don't let the wait discourage you from acting now. If you need help, current options (tirzepatide, semaglutide) are genuinely effective while you watch the TRIUMPH data roll in.

Medical Disclaimer: This article is for informational purposes only. Retatrutide is an investigational drug not approved by the FDA. Nothing on this page constitutes medical advice. Consult a licensed healthcare provider before starting any weight-loss treatment. Peptide suppliers mentioned operate in a regulatory gray area; use at your own risk.